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1. Introduction 
Mumps is an acute viral infection caused by a member of the Rubulavirus genus in the 
Paramyxoviridae family. Although it is mostly a childhood disease, with peak incidence 
occurring among those aged 5–9 years, mumps virus (MuV) may also affect teenagers. MuV 
is known to affect the salivary glands causing parotid swelling; however, it can also produce 
an acute systemic infection involving glandular, lymphoid and nervous tissues, leading to 
some important complications such as pancreatitis, oophoritis orchitis, mastitis, nephritis 
and thyroiditis. The main central nervous system (CNS) complication of mumps virus 
infection is aseptic meningitis (in up to 15% of cases); it is also associated rarely with 
encephalitis, hydrocephalus and sensorineural deafness (affecting approximately 5/100 000 
mumps patients) (Carbone & Rubin, 2007; Hviid et al., 2008; Plotkin & Rubin, 2007; World 
Health Organization [WHO], 2007). 
Massive vaccination programs have decreased the incidence of MuV infection worldwide, 
before the introduction of live attenuated mumps virus vaccines, mumps was the main 
cause of virus-induced disease in the CNS of children; indeed, the annual incidence of 
mumps in the absence of immunization was in the range of 100–1000 cases/100 000 people. 
Although vaccination programs have decreased the incidence of mumps virus infection, 
outbreaks have not been completely eliminated (WHO, 2007). The main problems associated 
with MuV vaccination are lack of protection due to vaccine failure and presentation of 
secondary adverse complications due to the use of relatively virulent vaccine strains; 
indeed, L-Zagreb, Leningrad-3 and Urabe AM9 strains have been associated with post-
vaccinal aseptic meningitis (Brown et al., 1991; Dourado et al., 2000; Galazka et al., 1999; 
Goh, 1999). The unacceptably high rate of vaccine associated meningitis and parotitis cases 
has resulted in vaccine withdrawal and public resistance to mumps vaccination (Schmitt et 
al., 1993). In consequence, mumps epidemics have re-emerged, and the incidence is rising in 
several countries (Choi, 2010; Dayan et al., 2008). 
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2. Wild-type mumps virus natural infection and CNS involvement 
2.1 Mumps virus 
Mumps virus (MuV) is a member of the Rubulavirus genus of the Paramyxoviridae family. 
Mumps virions are pleomorphic particles ranging from 100 to 600 nm in size, consisting of a 
helical ribonucleocapsid surrounded by a host cell-derived lipid envelope. Full-length 
genome is a non-segmented, single-stranded RNA of negative polarity that consists of 
15,384 nucleotides containing 7 genes that code for the nucleoprotein (NP), phosphoprotein 
(P), matrix (M), fusion (F), small hydrophobic (SH), hemagglutinin-neuraminidase (HN), 
and large (L) proteins. The genomic organization of the virus from 3´ to 5′ ends is NP-P-M-
F-SH-HN-L (Lamb & Parks, 2007; Pringle, 1997).  
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Fig. 1. Schematic diagram of mumps virus (not drawn to scale). On the surface of the viral 
membrane 3 glycoproteins are anchored: HN, F and SH. The M protein is located inside of 
the viral envelope. In the center of the virion is the ribonucleoprotein complex formed by 
the nucleocapside (NP:RNA) and viral RNA polymerase (P:L). Information based on the 
references: Carbone & Rubin, 2007; Santos-López et al., 2004. 
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A schematic diagram of the virion and functions of viral proteins are shown in figure 1. On 
the surface of viral particles and infected cells are projected two glycoproteins, F and HN, 
which are transmembrane glycoproteins of types I and II, respectively. HN glycoprotein is 
responsible for mumps virus attachment; it binds to sialic acid-containing cell receptors. Its 
neuraminidase (sialidase) activity releases the sialic acid residues from viral progeny to 
prevent self-aggregation during budding; HN glycoprotein also activates the F glycoprotein, 
which promotes the fusion between viral and cell membranes (Carbone & Rubin, 2007; 
Lamb & Parks, 2007).  
SH is an integral membrane protein without well-known properties; despite this, SH protein 
has been reported to block the TNFǂ mediated apoptotic signaling pathway; therefore it has 
been involved in evasion of the host anti-viral response (Wilson et al., 2006), so it has been 
proposed as a virulence factor, however, this issue is still controversial (T. Malik et al., 2011; 
Woznik et al., 2010). Likewise, the sequence of the mumps virus SH gene varies greatly from 
strain to strain and has therefore been used in molecular epidemiological studies to group 
mumps virus strains (Orvell et al., 1997). 
Inside the envelope lies a helical nucleocapsid core containing the RNA genome and the NP, 
P, and L proteins, which are involved in virus replication. NP protein is an RNA-binding 
protein that coats and protects full-length viral (-) sense genomic and (+) sense antigenomic 
RNAs to form the helical nucleocapsid template (Carbone & Rubin, 2007; Lamb & Parks, 
2007). Each NP protein interact with 6 nucleotides of the viral genome, therefore a full-
length genome polyhexameric may be required for efficient viral replication (process known 
as, Rule of Six) (Kolakofsky et al., 1998, 2005; Vulliemoz & Roux, 2001). P and L proteins 
form an enzymatic complex with RNA-dependent RNA polymerase activity; where L 
protein has the catalytic domain for RNA polymerization, whereas P protein functions as a 
cofactor for L protein and is able to bind the ribonucleoprotein complex (RNA-NP) 
(Kingston et al., 2004; Lamb & Parks, 2007). 
M protein resides between the envelope and the nucleocapside core; this is the most 
abundant protein in the virion, and it serves to physically link the ribonucleocapsid with the 
host cell membrane to promote the viral assembly process (Carbone & Rubin, 2007; Lamb & 
Parks, 2007). 
Two nonstructural proteins, V and I, are encoded by the P gene and are synthesized as a 
result of co-transcriptional editing of messenger RNA (mRNA) (Carbone & Rubin, 2007; 
Paterson & Lamb, 1990). In this process the viral polymerase moves repeatedly (process 
known as, stuttering) in a region known as “editing site” of the P gene, which is rich in 
citidine nucleotides (3’CCCCCC 5') inserting some non-template guanidine (G) nucleotides 
in the nascent transcript (Hausmann et al., 1999; Paterson & Lamb, 1990; Vidal et al., 1990). 
This editing mechanism involves the production of mRNAs whose ORFs are altered by 
insertion of G residues (Figure 2); so, the translation of full-transcript (unedited) encodes a V 
protein, which plays a role in circumventing the interferon (IFN) mediated antiviral 
responses by blocking IFN signaling and limiting IFN production  (Didcock et al., 1999a, 
1999b; Fujii et al., 1999; Rodriguez et al., 2003; N. H. Rosas-Murrieta et al., 2010); while, 
mRNAs generated by inserting 2 and 4 G residues encode a P and I proteins respectively. 
The generated proteins have the same N-terminus, but differ in their C-terminus (Lamb & 
Parks, 2007). 
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Fig. 2. Schematic representation of mumps virus P gene and mRNA editing mechanism (not 
drawn to scale). By a stuttering mechanism in the editing site of P gene, the viral polymerase 
introduces non-template G residues in the nascent transcript, which generates mRNAs with 
different ORFs, so, the translation of full-transcript (unedited) encodes a V protein, while 
mRNAs generated by inserting 2 and 4 G residues encode P and I proteins respectively. 
AUG and UGA sequence indicate the start and stop codons, respectively. Information based 
on the references: Hausmann et al., 1999; Lamb & Parks, 2007; Paterson & Lamb, 1990; Vidal 
et al., 1990. 
2.2 Viral pathogenesis and invasion central nervous system 
Natural infection with mumps virus is restricted to humans and is transmitted via the 
respiratory mucosa by direct contact, droplet spread or contaminated fomites. The 
incubation period is about 15 to 24 days (average 19 days). Infected patients become most 
contagious 1 to 2 days before onset of clinical symptoms and continue for several days 
afterwards (Hviid et al., 2008). Mumps virus initially infects the upper-respiratory-tract 
mucosa where it undergo a first replication cycle and then the progeny viruses spread to 
local lymph nodes where they undergo a second replication followed by a systemic spread 
with involvement of glandular, nervous and other target organs (figure 3) (Carbone & 
Rubin, 2007; Enders, 1996; Plotkin & Rubin, 2007). 
The main clinical manifestation of mumps is parotid swelling. However, parotitis is not a 
primary or necessary step of mumps virus infection. Mumps virus can also infect urinary 
tract, genital organs, pancreas, kidney and central nervous system (CNS). It is not yet well-
known how mumps virus spreads to the CNS, however, studies in newborn hamster model 
suggest that virus spreads by passage of infected mononuclear cells across the epithelium to 
epithelial cells of the choroid plexus (Fleischer & Kreth, 1982; Wolinsky et al., 1976). 
Alternatively, direct spread of virus is possible. At this site virus is replicated and released 
persistently from ependymal and choroidal cells, followed by deeper spread into the brain 
parenchyma causing encephalitis and several neurological complications. There are few 
data on the histopathology of the brain in mumps encephalitis (since death is rare). The data 
show the characteristic picture of a parainfectious process, characterized by perivenous 
demyelinisation and perivascular infiltration with mononuclear cells (Hviid et al., 2008). 
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Fig. 3. Pathogenesis of mumps virus infection. Mumps virus is acquired trough the upper-
respiratory-tract mucosa (1); where it undergo a first replication, after that new viruses 
spread (2) to local lymph nodes followed by a systemic spread with involvement of 
glandular and nervous tissues causing various diseases (3); finally virus is transmitted to 
another person through droplets or fomites (4). Based on the reference, Enders, 1996. 
2.3 Aseptic meningitis and other neurological complications of mumps 
Infection of the CNS is the most common extra-salivary gland manifestation of mumps virus 
infection, being aseptic meningitis the most frequent complication. Although the disease is 
usually mild should not be underestimated, mumps meningitis affects to 10%-15% of 
individuals infected by MuV, which is characterized by the sudden onset of fever with signs 
and symptoms of meningeal involvement as evidenced by changes in cerebrospinal fluid 
properties, including pleocytosis in absence of bacteria (Bonnet et al., 2006; Plotkin & Rubin, 
2007). 
Another less frequent but more serious complication of mumps virus infection is 
encephalitis (0.02-0.3% cases), which can lead to permanent neurologic damage including 
paralysis, seizures, hydrocephalus and even cause death. Likewise mumps virus infection is 
a major cause of sensorineural deafness in childhood and affects five per 100,000 patients 
(Bonnet et al., 2006; Hviid et al., 2008; Plotkin & Rubin, 2007; WHO, 2007).  
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3. Mumps vaccination 
Safe and efficacious vaccines against mumps - based on live, attenuated viral strains – have 
been available since the 1960s. In most regions of the world the annual incidence of mumps 
in absence of vaccination ranges from 100 to 1000 per 100 000 of the general population 
(WHO, 2007). In 2010, the World Health Organization indicated that 61% of countries 
(figure 4) have incorporated mumps vaccination into their national immunization programs, 
in most cases using combined measles–mumps–rubella (MMR) vaccine (WHO, 2010). 
 
Fig. 4. Countries that have incorporated mumps vaccination in their national immunization 
programs. Yellow and gray indicate the countries immunized (61%) and unimmunized 
(39%) respectively. Source: WHO/IVB database, 193 WHO Member States, Data as of July 
2010. Date of slide: 19 August 2010. 
3.1 Effects of vaccination on epidemic mumps 
Use of mumps vaccine (usually administered in measles-mumps-rubella or measles-
mumps-rubella-varicella vaccines) is the best way to prevent mumps. Mumps immunization 
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has been effective at controlling epidemic mumps infection and complications associated 
with it has been drastically reduced,. This is the reason why the WHO defined viral mumps 
as a disease preventable by vaccination (vaccine-preventable) (WHO, 2007). In countries 
where there is no vaccination against mumps, its incidence remains high, with epidemic 
peaks every 2–5 years and those aged 5–9 years consistently being the most affected. In the 
pre-vaccine era, mumps was a common infectious disease with a high annual incidence, 
usually >100 per 100 000 population (Dayan et al., 2008; Galazka et al., 1999). It was a very 
common disease in U.S. children, with as many as 300,000 cases reported every year. After 
the introduction of mumps virus vaccine in United States in 1967, cases dropped by 98%, 
from 152,209 cases in 1968 to 2982 cases in 1985. Since 1989, the incidence of mumps has 
declined, with 266 reported cases in 2001. This decrease is probably due to the fact that 
children have received a second dose of mumps vaccine (part of the two-dose schedule for 
measles, mumps, rubella or MMR).  Studies have shown that the effectiveness of mumps 
vaccine ranges from 73% to 91% after 1 dose vaccines and from 79% to 95% after 2 doses. 
However, we can not let our guard down against viral mumps (Centers for Disease Control 
and Prevention [CDC], 2010a). 
Despite mumps epidemics have decreased from the incorporation of mumps vaccine, in the 
late 1980s, mumps outbreaks have occurred in both unvaccinated and vaccinated 
adolescents and young adults. From October 1988 to April 1989 a mumps epidemic was 
reported in Douglas County, Kansas; of the 269 cases, 208 (77.3%) occurred among primary 
and secondary school students, of whom 203 (97.6%) had documentation of mumps 
vaccination. These data suggested that both mumps vaccine failure and the lack of 
vaccination have contributed to the relative resurgence of mumps. Therefore a change in 
immunization policy was recommended to two-dose schedule of measles-mumps-rubella 
vaccine, which should help reduce the occurrence of mumps outbreaks in highly vaccinated 
populations (Hersh et al., 1991). The widespread use of a second dose of mumps vaccine 
among U.S. schoolchildren beginning in 1990 was followed by low reports of mumps cases; 
which was established at 2010 elimination goal, however, various mumps outbreaks have 
been reported in several countries at different years (Brockhoff et al., 2010; CDC, 2010b; 
Cheek et al., 1995; Dayan et al., 2008; Dayan & Rubin, 2008; Park et al., 2007; Vandermeulen 
et al., 2009; Vandermeulen et al., 2004). These reports have suggested that secondary vaccine 
failure played an important role in mumps outbreaks, thus a more effective mumps vaccine 
or changes in vaccine policies may be considered to prevent future outbreaks. 
3.2 Vaccine strains: preparation, attenuation, induced immune 
Mumps vaccines are available in the form of live attenuated virus and may be given alone or 
in combination with measles and rubella vaccines, according to recommendations from the 
World Health Organization (WHO, 2007). Mumps viruses are attenuated by adaption in 
embryonated chicken eggs, chicken or quail embryo fibroblasts or human diploid cells. 
Through these processes virus mutants are selected because of their increased ability to 
replicate under new culture conditions but with a reduced capacity to produce disease but 
stimulating immunity in the natural host (Brown & Wright, 1998; Plotkin & Rubin, 2007). 
There are more than 10 strains of mumps virus used as vaccines (Table 1), which induce 
different levels of seroconversion (80-99%) and protective efficacy (70-95%). Nowadays, the 
most often used vaccine strains are Jeryl Lynn, RIT 4385, Urabe-AM9, L-Zagreb and 
Leningrad-3 (Bonnet et al., 2006). The first live attenuated mumps virus vaccine, Jeryl Lynn 
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B (introduced in the U.S.A in 1967), represents an ideal vaccine because it induces 
neutralizing antibodies in 95%-98% of vaccinees and few side effects have been associated 
with its application (Carbone & Rubin, 2007). The Jeryl Lynn strain was attenuated by 
passage in embryonated hen’s eggs and chicken embryo cell culture (Plotkin & Rubin, 2007). 
The RIT 4385 mumps vaccine was derived from a Jeryl Lynn clone (JL-1) by passage through 
chicken embryo fibroblast cultures. Comparative studies of the RIT 4385 and Jeryl–Lynn 
vaccines showed similar seroconversion rates (96-98% for RIT 4385 and 97% for Jeryl Lynn) 
although the geometric mean titre was significantly higher among recipients of the Jeryl–
Lynn vaccine (Crovari et al., 2000; Kanra et al., 2000; Lim et al., 2007). The Urabe Am9 strain 
was developed by the Biken Institute in Japan from an isolate obtained from the saliva of a 
mumps patient. Urabe Am9 strain preparations are produced either in the amnion of 
embryonated hen’s eggs or in chicken embryo cell cultures. Seroconversion rates in children 
aged 12–20 months range from 92–100%. The Rubini mumps vaccine virus was derived 
from a mumps isolate obtained from the urine of a child in Switzerland in 1974.  
Comparative efficacy of Rubini, Jeryl-Lynn and Urabe strain mumps vaccine were 80.7, 54.4 
and -55.3%, respectively. Thus, Rubini vaccine was discontinued due to poor efficacy (Goh, 
1999; Ong et al., 2005). The Leningrad-3 strain was developed in the 1950s in guinea pig 
kidney cell cultures, with further passages in Japanese quail embryo cultures. The 
Leningrad-3 vaccine strain has achieved seroconversion rates of 89–98% in children aged 1–
7 years and protective efficacy ranged from 92% to 99%. The Leningrad-3 mumps virus was 
further attenuated in Croatia by adaptation and passages on chicken embryo fibroblast cell 
cultures. The new mumps strain, designated L-Zagreb, is used in Croatia and India (Bonnet 
et al., 2006; Plotkin & Rubin, 2007; WHO, 2007). 
 
Vaccine 
strain 
Cell 
substrate
Sero-
conversión
Protective 
efficacy 
Manufacturer Main area of 
distribution 
Jeryl-Lynn CWE 80-100% 72.8- 91% Merck Worldwide 
RIT 4385 CWE 96-98.1% GlaxoSmithKline Worldwide 
Leningrad- 3 QEF 89-90% 92-99% Bacterial Medicine 
Institute, Moscow
Russia 
Leningrad-
Zagreb 
CEF 89-98% 92-99% Institute of Immunology of 
Zagreb
Yugoslavia 
Urabe AM9 EHE
CEF
92-100% 54.4%- 93% Sanofi Pasteur
Biken
Worldwide 
Japan 
Rubini HDCS N I 0-33% Swiss Serum Institute Discontinued 
Hoshino CEF N I N I Kitasato Institute Japan 
Torii CEF N I N I Takeda Chemicals Japan 
Miyahara CEF N I N I Chem-Sero Therapeutic 
Research Institute 
Japan 
NL M-46 CEF N I N I Chiba Japan 
S-12 HDCS N I N I Razi State Serum and 
Vaccine Institute 
Iran 
NI, No Information; CEF, chicken embryo fibroblasts; HEF, human embryo fibroblasts; QEF, quail 
embryo fibroblasts; EHE, embryonated hen’s eggs; HDCS, human diploid cells. 
Information based on the following references: Bonnet et al., 2006; Dayan & Rubin, 2008; Dourado et al., 
2000; Galazka et al., 1999; Lim et al., 2007; Peltola et al., 2007; Plotkin & Rubin, 2007; WHO, 2007.  
Table 1. Live attenuated mumps vaccine stains.  
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4. Adverse reactions  
In general, adverse reactions to mumps vaccination are rare and mild. Apart from slight 
soreness and swelling at the injection site, local reactions, low-grade fewer, parotitis, and 
rashes are the most common adverse events. Occasionally, orchitis and sensorineural 
deafness have been observed after mumps virus vaccination (WHO, 2007).  
In a comparative study of the Jeryl Lynn, Urabe, and Leningrad-Zagreb strains in MMR 
combination vaccines, the frequency of parotitis in vaccinated children was 0-5%, 1-3%, and 
3-1%, respectively, compared with 0-2% in unvaccinated controls (Hviid et al., 2008).  
A recent study reported adverse reactions following immunization with MMR vaccine 
that contain the live attenuated mumps virus Hoshino strain; Parotitis was the most 
frequent event occurring in 1.8% of recipients, followed by fever and convulsions 
(0.03%), convulsions (0,16%), encephalopathy (0,004%), and anaphylactic reactions 
(0,004%) in children vaccinated at 12 months and at 4 to 6 years of age (Esteghamati et 
al., 2011). 
4.1 Post vaccine meningitis 
One of the most frequent side effects associated with mumps virus vaccine is aseptic 
meningitis which is also the most frequent complication of naturally acquired mumps 
infection (Table 2). In November 2006, the Global Advisory Committee on Vaccine Safety 
(GACVS) reviewed adverse events following mumps vaccination with special reference to 
the risk of vaccine associated aseptic meningitis (WHO, 2007). Cases of aseptic meningitis 
and estimates of incidence rates have been reported following the use of the Urabe Am9, 
Leningrad–Zagreb, Hoshino, Torii and Miyahara strains from various surveillance systems 
and epidemiological studies. The reported rate of aseptic meningitis that occurs after 
vaccination ranges widely, from approximately 1 in 1.8 million doses for the Jeryl Lynn 
strain to as high as 1 in 1000 for the Leningrad-3 strain (Bonnet et al., 2006).  However, due 
to the variability of the methods used in the different studies, no clear conclusion can be 
drawn on the differences in risk for this complication among these strains. 
Urabe AM9 strain was introduced in Canada and UK in 1986 as part of the MMR vaccine. In 
September 1992, the Urabe AM9-strain was withdrawn from the market worldwide 
following data indicating a higher rate of vaccination-related cases of meningitis (Schmitt et 
al., 1993). Despite this, Urabe AM9 strain continued in use several years later in some 
developing countries including but not limited to Mexico and Brasil (Dourado et al., 2000; 
Santos-López et al., 2006).  
The first reports suggesting a relationship between MMR vaccine (which contained mumps 
virus strain Urabe AM9, measles virus strain Schwarz and rubella virus strain RA 27/3) and 
aseptic meningitis showed an estimated incidence of 1/62,000 administered doses (Furesz & 
Contreras, 1990). Reports of meningitis in patients immunized with Urabe AM9 strain range 
from 1/233,000 to 16.6/10,000 administered doses (Kimura et al., 1996; Schmitt et al., 1993). 
An outbreak of aseptic meningitis following the mass immunization campaign with an 
Urabe-containing vaccine was reported, with an estimated risk of aseptic meningitis 1 per 
14,000 doses. This study confirms a link between measles-mumps-rubella vaccination and 
aseptic meningitis (Dourado et al., 2000). Likewise, no serious adverse effects have been 
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Vaccine 
strain 
Genetic 
heterogeneity 
Cases of aseptic 
meningitis/dose 
administered 
Estimated cases of 
meningitis/100,000 
dose 
Reference 
Jeryl-Lynn 
Composed of two 
distinct viral 
strains: JL1 and 
JL2 
(Amexis et al., 
2002) 
0.1/100,000  to 
2/500,000 
0,1 to 0,4 
 
Bonnet et al., 2006; Makela 
et al., 2002 
Urabe AM9 
Composed of 
quasispecies mix,
(Sauder et al., 
2006) 
1/233,000 to 
16.6/10,000 
0,4 to 166 
 
Dourado et al., 2000; Furesz 
& Contreras, 1990; Kimura 
et al., 1996; Miller et al., 
2007; Rebiere & Galy-
Eyraud, 1995; Schmitt et al., 
1993; Sugiura & Yamada, 
1991 
Leningrad- 
3 
Composed more 
than one viral 
variant 
(Boriskin et al., 
1992) 
2/10,000 to 1/1000
20 to 100 
 
Cizman et al., 1989; Plotkin 
& Rubin, 2007; WHO, 2007 
Leningrad-
Zagreb 
Composed of two 
major variants: A 
and B. 
(Kosutic-Gulija et 
al., 2008) 
1/19,247 to 
1/ 3,390 
 
5,1 to 29,5 
 
Arruda & Kondageski, 
2001; da Cunha et al., 2002; 
da Silveira et al., 2002; 
Phadke et al., 2004 
RIT 4385 
One strain, clone 
JL1 
(Tillieux et al., 
2009) 
1/525,312 0,19 
Bonnet et al., 2006; 
Schlipkoter et al., 2002 
Table 2. Genetic heterogeneity and Incidence of postvaccine aseptic meningitis. 
related to vaccination with RIT 4385 mumps virus strain (Lim et al., 2007). Little 
epidemiological information is available for other vaccines. Leningrad-Zagreb strain-
containing vaccines have been associated with a high rate of aseptic meningitis (da Cunha et 
al., 2002; da Silveira et al., 2002); however, other reports indicate no evidence to link 
Leningrad-Zagreb strain with aseptic meningitis (Kulkarni et al., 2005; Sharma et al., 2010). 
Although high rates of aseptic meningitis ((1/1000 vaccine recipients) have been reported 
for vaccines containing Leningrad-3 mumps virus strain the evidence confirming causal 
association is limited (Cizman et al., 1989).  
5. Virulence and attenuation of mumps virus strains 
Problems with attenuated virus vaccines generally reflect under- or over-attenuation or lack 
of efficacy respectively. Different studies have attempted to establish molecular markers 
allow discrimination between an attenuated strain and a virulent strain, nevertheless, the 
genetic basis for attenuation are still not completed known for any of the mumps vaccines. 
Likewise the lack the laboratory studies that assure the absence of residual neurotoxicity in 
mumps vaccine has been a serious problem, as demonstrated by the occurrence of aseptic 
meningitis in recipients of certain vaccine strains. Thus, some vaccines found to be 
www.intechopen.com
 
Studies on the Association of Meningitis and Mumps Virus Vaccination 
 
189 
neuroattenuated in monkeys were later found to be neurovirulent in humans when 
administered in large numbers (Rubin & Afzal, 2011).  
5.1 Genetic characterization of post vaccination virus isolates (Helvetica, 9pt, bold) 
The first reports suggesting a relationship between Urabe AM9 strain with the occurrence of 
aseptic meningitis, suffer however of a lack of molecular markers to discriminate between 
vaccine- (attenuated) and wild-type strains of the virus, making it difficult to differentiate 
whether the patient had an infection caused by vaccine or wild type virus. Several 
laboratories were able to differentiate Urabe AM9 strain from wild-type isolates of mumps 
virus by RT-PCR and partial sequence analysis of the P, SH, F and HN genes, confirming 
that mumps virus isolates from post-vaccination meningitis correspond to Urabe AM9 
strain, establishing a causal association of virus strain with post-vaccination meningitis 
(Brown et al., 1991; Forsey et al., 1990; Yamada et al., 1990).  
Analysis of cDNA sequences of several isolates from vaccine-associated meningitis and 
parotitis cases demonstrated that Urabe AM9 strain consisted of a mixture of virus variants 
that could be distinguished based on the sequence of the hemagglutinin-neuraminidase 
gene (HN) at nt 1,081 (nt 7,616 of the genome). Viruses containing an A residue at nt 1081 
and encoding a lysine at amino acid position 335 were isolated from cases of post-
vaccination parotitis or meningitis whereas viruses containing a G residue at nt 1081 that 
codes for a glutamic acid (aa 335) were not associated with post-vaccination disease, 
suggesting A1081 (K335) was a marker of neurovirulence and G1081 (E335) was a marker of 
attenuation (Brown et al., 1996). The identification of an A residue at position 1081 in the 
HN gene sequenced from samples of either patients with post-vaccination meningitis (Afzal 
et al., 1998; Wright et al., 2000) and patients infected with the wild-type strain (Cusi et al., 
1998), supported the previous hypothesis.  
However, this hypothesis was questioned by other researchers, reporting that some 
UrabeAM9 vaccine lots encoding K355 did not lead to adverse events in vaccinees (Amexis et 
al., 2001; Mori et al., 1997). Moreover, K335 was also found in the HN glycoprotein of the 
Jeryl Lynn vaccine strain, a widely used vaccine not associated with aseptic meningitis 
(Mori et al., 1997). Nonetheless, Jeryl Lynn strain differs from Urabe AM9 at more than 900 
nucleotides, so its safety is likely determined by a number of other genetic changes.  
By comparison of the HN gene sequences of several Urabe AM9 vaccine derived isolates, 
Afzal et al., showed that those sequences differed at several other sites (M89V; N464K; 
N498D), complicating the interpretation of the initial findings (Afzal et al., 1998). Moreover, 
heterogeneity at position 464 in the HN glycoprotein (Asn464/Lys) was also reported from 
sequence analysis of Urabe AM9 vaccine virus and post-vaccination meningitis isolates 
(Afzal et al., 1998; Amexis et al., 2001; Wright et al., 2000). Further,  it was shown that Urabe-
AM9 strain is constituted by several virus quasispecies that differ in distinct sites all along 
their genome, with several amino acids changes in the NP, P, L (involved in 
replication/transcription), F and HN proteins (involved in the recognition, fusion and 
release of virus in infected cells), as well as in the intergenic region NP-P (Shah et al., 2009).  
Sauder et al., showed that genetic heterogeneity at the specific genome sites have a 
profound effect on the neurovirulent phenotype of Urabe-AM9 strain (Sauder et al., 2006), 
suggesting there is not a unique genetic marker responsible for virus attenuation, rather the 
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combination of mutations may be necessary for an adequate viral attenuation (Amexis et al., 
2001; Sauder et al., 2006; Shah et al., 2009). 
Different vaccine strains exhibit high degree of nucleotide heterogeneity (table 2) across 
their entire genome making it impossible to determine which genetic change is associated 
with neurovirulence or neuroattenuation. At respect, the Jeryl Lynn strain contains a 
mixture of two substrains (JL1 and JL2) that presented 414 nucleotide differences (2.69%), 
leading to 87 amino acid substitutions (1.67%). Subsequent passage of Jeryl Lynn strain in 
Vero or CEF cell cultures resulted in rapid selection of the major component JL1, while 
growth in embryonated chicken eggs (ECE) favored accumulation of the minor component 
JL2 (Afzal et al., 1993; Amexis et al., 2002; Chambers et al., 2009). Meanwhile, Leningrad-3 
strain was characterized as heterogenic on the basis of plaque morphology and with several 
ambiguities in P and F genes (Boriskin et al., 1992). L-Zagreb vaccine strain was developed 
by further subcultivation of Leningrad-3 mumps vaccine strain in primary culture of 
chicken embryo fibroblast (CEF) and its heterogeneity was identified throughout the entire 
genome (Kosutic-Gulija et al., 2008). 
5.2 Structural, functional and antigenic analysis of mumps virus proteins 
Mumps vaccine strains, including L-Zagreb, Leningrad-3 and Urabe AM9, have been 
associated with a high incidence of post-vaccination aseptic meningitis. Although several 
researchers have focused to study the genetic basis of mumps virus strains 
virulence/attenuation, there is not genetic marker that help to discriminate between a 
virulent strain and an attenuated strain. Previous analyses confirmed that Jeryl Lynn, 
Urabe-AM9, Leningrad-3 and L-Zagreb mumps virus strains are genetically heterogeneous, 
where each nucleotide changes may contribute to neurovirulence-neuroattenuation of the 
vaccine. Therefore, caution should be exercised when evaluating genetic markers because 
more than one nucleotide can influence the attenuation or virulence of a vaccine (Sauder et 
al., 2006). By other side, functional analysis of point mutations gives relevant information 
about the properties of a virus variant. A point mutation from guanine (G) to adenine (A) at 
nucleotide position 1081 in the hemagglutinin-neuraminidase (HN) gene has been 
associated with neurovirulence of Urabe AM9 mumps virus vaccine. This mutation 
corresponds to a glutamic acid (E) to lysine (K) change at position 335 in the HN 
glycoprotein. We have experimentally demonstrated that two variants of Urabe AM9 strain 
(HN-A1081 and HN-G1081) differ in their replication efficiency in cell culture, where HN-A1081 
variant was efficiently replicated in both human neuroblastoma cells (SHSY5Y) and 
newborn rat brain (105 and 104 PFU respectively), whereas HN-G1081 variant was replicated 
at low titers (102 PFU in both cases) (Santos-Lopez et al., 2006). These findings can be 
explained in part by differences in cell receptor binding affinity of each variant, where HN-
A1081 variant showed highest affinity towards ǂ2-6 linked sialic acids that are highly 
expressed in human nerve cells, whereas HN-G1081 viral variant showed higher affinity 
towards ǂ2-3 linked sialic acids that are less expressed in nerve cells, however this latter 
variant also recognized ǂ2-6 linked sialic acid but with lesser affinity than HNA1081 virus 
(Reyes-Leyva et al., 2007). Controversially, two mumps virus that differ at position 335 
(K/E) of HN protein exhibited similar growth kinetics in neuronal (SHSY5Y) and non 
neuronal cell lines (Vero cells) and similar neurotoxicity when tested in rats models. This 
suggests that amino acid 335 is not a crucial determinant of Urabe neurovirulence, 
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nevertheless this point mutation can not be excluded as contributing to vaccine virulence 
(Sauder et al., 2009).  
Likewise, we have performed a structure-function analysis of that amino acid substitution, 
suggesting that the E/K interchange does not affect the structure of the sialic acid binding 
motif; however, the electrostatic surface differs drastically due to an exposed short alpha 
helix. Consequently, this mutation may affect the accessibility of HN to substrates and 
membrane receptors of the host cells (Santos-Lopez et al., 2009). These results suggest that 
the change K335E affects the biological activity of HN glycoprotein, conferring 
neurotropism for HN-A1081 viral variant as previously proposed (Brown et al., 1996; Wright 
et al., 2000). Amino acid 335 is located at an important domain of HN glycoprotein that 
involves the recognition of an antigenic site, thus all virus variants that possess a Glu at 
position 335 were completely neutralized, while those containing Lys escaped neutralization 
(Afzal et al., 1998). 
Using a rat based model of mumps neurovirulence, Shah et al. demonstrated that viral 
variants with a Glu at position 335 of HN glycoprotein is significantly attenuated 
(hydrocephalus 1.37% ± 0.50) compared to a virus isolated from a patient with post-
vaccination meningitis (hydrocephalus 4.70%±0.77) and compared with wild type 
(hydrocephalus 11.47%±1.16) which have Lys at this position (Shah et al., 2009). 
The importance of amino acid 464 in the HN glycoprotein was demonstrated by mumps 
virus reverse genetic, which showed that N464S substitution is involved in virus replication 
in nerve cells (SH-SY5Y) (Ninomiya et al., 2009). Crystal structure studies of the HN 
glycoprotein of a closely related paramyxovirus Newcatle disease virus, indicates that 
amino acid position 466 may be at or near the active site of the HN protein (Crennell et al., 
2000), thus the substitution around this site (464) might affect enzymatic activity of HN 
protein and might change the cell specificity of mumps virus. Amino acids 464-466 form a 
potential N-liked glycosylation site given that substitutions at this site were predicted to 
result in loss of N-linked glycosylation, and affect virus tropism and virulence (Rubin et al., 
2003). Similarly, Malik et al., demonstrated that Ser-466Asp substitution in the HN protein 
resulted in decreased receptor binding and neuraminidase activity, Ala91Thr change in the 
fusion protein resulted in decreased fusion activity, and that Ile736Val substitution in the 
polymerase resulted in increased replication and transcriptional activity (Malik et al., 2007; 
Malik et al., 2009). 
A study based on the extent of hydrocephalus induced in the rat brain after intracerebral 
vaccine inoculation showed that expression of the F gene of the neurovirulent Kilman strain 
alone was sufficient to induce significant levels of hydrocephalus, this experiment confirms 
the importance of surface glycoproteins in neuropathogenesis (Lemon et al., 2007). 
Moreover, recent studies done in the rat model demonstrated the ability of 
nucleoprotein/matrix protein of the Jeryl Lynn vaccine strain to significantly neuroattenuate 
wild-type 88-1961 strain, which is highly neurovirulent (Sauder et al., 2011)   
6. Innate immune response against mumps virus infection 
Innate immune response acts as a first line of defense during viral infections, through 
immunoregulatory mechanisms that increase own innate immune response and stimulate 
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an adaptive immune response. After viral infection, intracellular signaling events are 
activated and innate cytokine expression are induced as interleukins (IL), tumor necrosis 
factor (TNF) and interferon (IFN) (Biron & Sen, 2007; Pestka, 2007). 
Type-I IFNs (IFN-ǂ/ǃ) are a superfamily of cytokines that were discovered as a result of 
their induction by and action against virus infections. The interaction between Toll-like 
receptors (TLR) and pathogen-associated molecular patterns (as genomic RNA and viral 
proteins), triggers the activation cell signaling pathways that promote activation of some 
transcription factors such as IRF3 and NFκB, which are necessary to induce expression of 
IFN-ǃ. Analogously, RNA helicase molecules (RIG-I and mda-5) trigger TLR-independent 
pathways that respond to viral nucleic acids (such as dsRNA) generated in the cytoplasm by 
viral replication, causing activation of IRF3 and NFκB, wich also promote the synthesis of 
IFN-ǃ (Conzelmann, 2005; Honda et al., 2005; Randall & Goodbourn, 2008; Xagorari & 
Chlichlia, 2008).  
The biological activities of IFNs are initiated by the recognition of IFN-ǂ/ǃ receptor 
(composed of the products of the IFNAR1 and IFNAR2 genes) on the cell surface, which 
results in the activation of a signaling pathway known as Jak/STAT pathways. This starts 
by activation of tysosine kinases Tyk2 and Jak1 located in the cytoplasmic tail of IFNAR1 
and IFNAR2 subunits respectively (de Weerd et al., 2007; Randall & Goodbourn, 2008). 
Activation of the signal transduction occurs when Tyk2 phosphorylates Tyr466 residue on 
IFNAR1, creating a docking site for STAT2, which is then phosphorylates on Tyr690. 
Phosphorylated STAT2 protein associates with STAT1, inducing its phosphorylation on 
Tyr701 by JAK1. Phosporylated Stat2 and Stat1 proteins form a stable heterodimer that 
creates a nuclear localization signal (NLS) that permits the transport of these dimers into the 
nucleus until their dephosphorylation (Randall & Goodbourn, 2008; Schindler et al., 2007). 
In addition, IFNAR2 subunit is acetylated at Lys399 and promotes the acetylation of IRF9, 
which is essential to DNA binding (Tang et al., 2007). Association of STAT1-STAT2 
heterodimer with IRF9 constitutes ISGF3 (IFN-stimulated gene factor 3) a heterotrimeric 
transcription factor that binds to the IFN-stimulated response element (ISRE), present in the 
promoters of several IFN-stimulated genes (ISG). The final step of this signaling pathway is 
the induction of gene transcription whose expression establishes the antiviral state (Biron & 
Sen, 2007; Randall & Goodbourn, 2008; Schindler et al., 2007; Sen, 2001).  
Numerous ISG products  have been described such as Caspases, which are involved in cell 
death; Protein kinase R (PKR) that inhibits both cellular and viral translation, through 
phosphorylation of NF-B and eIF2ǂ factor; 2´5´-oligoadenylate synthetase (OAS) that binds 
to and activates the RNase L, which promotes the degradation cellular and viral RNAs; Mx 
protein that binds nucleocapsid-like structures, thereby restricting virus replication and 
assembly (Honda et al., 2005; Randall & Goodbourn, 2008).  
6.1 Mumps virus and evasion of innate immune response 
Several viruses have evolved strategies to circumvent the antiviral state stimulated by IFN 
through the expression of proteins that antagonize components of the Jak-Stat signaling 
pathway, such as the V protein of paramyxoviruses (Gotoh et al., 2002; Randall & 
Goodbourn, 2008). As mentioned, mumps virus P gene codes for three polypeptides: V, I 
and P. Their mRNAs are translated by use of overlapping reading frames (ORFs) via 
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cotranscriptional insertion of nontemplated guanidine nucleotides (mRNA edition) (Lamb & 
Parks, 2007; Paterson & Lamb, 1990). Mumps virus V protein is a nonstructural protein that 
counteracts the IFN-induced antiviral response by different mechanisms. In some 
paramyxoviruses V protein interacts with and inhibits the activity of mda-5 (Andrejeva et 
al., 2004), but not RIG-I (Komatsu et al., 2007); in other viruses V inhibits interferon-
mediated antiviral response through degradation of STAT proteins and thus promotes viral 
replication (Gotoh et al., 2002; Horvath, 2004; Randall & Goodbourn, 2008). 
We have shown that two variants of Urabe AM9 vaccine strain (HN-A1081 and HN-G1081) 
that were initially characterized by their difference in the HN gene nt 1081, also differ in 
their replication efficiency in nerve cells, where HN-A1081 variant preferentially infects nerve 
cells, whereas HN-G1081 variant has limited replication in this cells (Santos-Lopez et al., 
2006); These results were associated with differences in the virus binding affinity towards 
cell receptors and enzymatic activity (Reyes-Leyva et al., 2007). Further experiments showed 
that differences in sensitivity to IFN determined the replication rate of Urabe AM9 mumps 
virus variants in nerve cells, where HN-G1081 variant was more sensitive to interferon (from 
102.5 to 101.3 TCID50) than HN-A1081 variant (from 103.5 to 102.6 TCID50). Moreover HN-
A1081 virus reduced the transcription of cellular IFN responsive genes such as STAT1, STA2, 
p48 and MxA in both unprimed and IFN-primed cells, whereas HN-G1081 virus just reduced 
MxA transcription. Sensitivity to IFN was associated with insertion of a non-coded glycine 
at position 156 in the V protein (VGly) of HN-G1081 virus variant, whereas resistance to IFN 
was associated with preservation of wild-type phenotype in the V protein (VWT) of HN-A1081 
virus variant (Rosas-Murrieta et al., 2007). Functional analysis of Gly 156 insertion suggested 
that VWT protein may be more efficient than VGly protein to inactivate both the IFN signaling 
pathway and antiviral response due to differences in their finest molecular interaction with 
STAT proteins (Rosas-Murrieta et al., 2010). 
On the other hand the activation of the JAK-STAT pathway by IFN simultaneously activates 
other processes regulated by IFN such as apoptosis. We studied the relationship between V 
protein variants of Urabe AM9 vaccine strain and IFN-ǂ induced apoptosis. Our results 
indicated that V proteins decrease the levels of caspases and DNA fragmentation, 
suggesting that VWT protein is a better modulator of apoptosis than Vgly in the vaccine 
strain (Rosas-Murrieta et al., 2011).  
7. Conclusions 
Several strains of mumps virus used as attenuated vaccines have been associated with post-
vaccination meningitis. Experimental data indicates that neurovirulence is a complex issue 
that involves multiple components either viral or cellular. Further studies are in progress to 
recognize the role of these in viral attenuation and virulence. 
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